Alpha 1 Biomedicals Inc. of Bethesda, Md., announced on Friday thatSciClone Pharmaceuticals Inc. has filed a motion in the U.S. DistrictCourt for the Northern District of California seeking certainpreliminary injunctive relief pending the outcome of an arbitrationproceeding between Alpha 1 and SciClone . On July 26, 1993, Alpha 1initiated an arbitration proceeding against SciClone in order toresolve a number of outstanding contractual disputes relating to alicense agreement between the two companies. SciClone holds alicense from Alpha 1 to commercialize Thymosin alpha 1, a treatmentfor hepatitis B, in all countries of the world other than the UnitedStates, Canada, Europe, Israel and Korea.

(c) 1997 American Health Consultants. All rights reserved.